Published in Nature on November 18, 2004
Patterns of somatic mutation in human cancer genomes. Nature (2007) 38.41
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med (2005) 25.93
The cancer genome. Nature (2009) 23.13
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci U S A (2008) 17.41
Characterizing the cancer genome in lung adenocarcinoma. Nature (2007) 16.48
Charting a course for genomic medicine from base pairs to bedside. Nature (2011) 9.39
Guidelines for the welfare and use of animals in cancer research. Br J Cancer (2010) 6.97
Analysis of oncogenic signaling networks in glioblastoma identifies ASPM as a molecular target. Proc Natl Acad Sci U S A (2006) 6.33
Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci U S A (2005) 4.70
Subtype and pathway specific responses to anticancer compounds in breast cancer. Proc Natl Acad Sci U S A (2011) 4.55
BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. PLoS Med (2007) 4.50
Mutation analysis of 24 known cancer genes in the NCI-60 cell line set. Mol Cancer Ther (2006) 4.09
Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. Nat Genet (2009) 3.80
Activation of tyrosine kinases by mutation of the gatekeeper threonine. Nat Struct Mol Biol (2008) 3.18
Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy. Br J Cancer (2010) 2.83
Evolutionary dynamics of cancer in response to targeted combination therapy. Elife (2013) 2.76
Rapid detection and profiling of cancer cells in fine-needle aspirates. Proc Natl Acad Sci U S A (2009) 2.75
Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval. J Natl Cancer Inst (2015) 2.31
Nanotechnology and cancer. Annu Rev Med (2008) 2.25
Predictive biomarkers: a paradigm shift towards personalized cancer medicine. Nat Rev Clin Oncol (2011) 2.02
The fibromatosis signature defines a robust stromal response in breast carcinoma. Lab Invest (2008) 1.85
Targeting the absence: homozygous DNA deletions as immutable signposts for cancer therapy. Proc Natl Acad Sci U S A (2007) 1.84
Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed. Future Med Chem (2012) 1.74
Combinatorial drug design targeting multiple cancer signaling networks controlled by mitochondrial Hsp90. J Clin Invest (2009) 1.72
Loss of p53 impedes the antileukemic response to BCR-ABL inhibition. Proc Natl Acad Sci U S A (2006) 1.71
Mechanisms and insights into drug resistance in cancer. Front Pharmacol (2013) 1.70
Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma. Biochem Pharmacol (2011) 1.59
β₁Integrin/FAK/cortactin signaling is essential for human head and neck cancer resistance to radiotherapy. J Clin Invest (2012) 1.56
Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy. Mol Cancer (2010) 1.56
Combined Inactivation of MYC and K-Ras oncogenes reverses tumorigenesis in lung adenocarcinomas and lymphomas. PLoS One (2008) 1.46
A Network of Conserved Synthetic Lethal Interactions for Exploration of Precision Cancer Therapy. Mol Cell (2016) 1.45
Evolution of resistance to targeted anti-cancer therapies during continuous and pulsed administration strategies. PLoS Comput Biol (2009) 1.43
BCR-ABL-transformed GMP as myeloid leukemic stem cells. Proc Natl Acad Sci U S A (2008) 1.34
A novel SND1-BRAF fusion confers resistance to c-Met inhibitor PF-04217903 in GTL16 cells through [corrected] MAPK activation. PLoS One (2012) 1.30
BreastMark: an integrated approach to mining publicly available transcriptomic datasets relating to breast cancer outcome. Breast Cancer Res (2013) 1.22
Evolution of acquired resistance to anti-cancer therapy. J Theor Biol (2014) 1.21
The biology of personalized cancer medicine: facing individual complexities underlying hallmark capabilities. Mol Oncol (2012) 1.21
Managing drug resistance in cancer: lessons from HIV therapy. Nat Rev Cancer (2012) 1.19
Targeting mutant BRAF in melanoma: current status and future development of combination therapy strategies. Cancer J (2012) 1.18
Efficient elimination of cancer cells by deoxyglucose-ABT-263/737 combination therapy. PLoS One (2011) 1.18
Targeted next-generation sequencing of DNA regions proximal to a conserved GXGXXG signaling motif enables systematic discovery of tyrosine kinase fusions in cancer. Nucleic Acids Res (2010) 1.17
Magnetic Nanoparticles and microNMR for Diagnostic Applications. Theranostics (2012) 1.17
Targeting the RTK-PI3K-mTOR axis in malignant glioma: overcoming resistance. Curr Top Microbiol Immunol (2010) 1.15
Mathematical models of targeted cancer therapy. Br J Cancer (2006) 1.11
Receptor-targeted nanocarriers for therapeutic delivery to cancer. Mol Membr Biol (2010) 1.11
PINCH1 regulates Akt1 activation and enhances radioresistance by inhibiting PP1alpha. J Clin Invest (2010) 1.09
Coordinated effects of microRNA-494 induce G₂/M arrest in human cholangiocarcinoma. Cell Cycle (2012) 1.08
Technology Insight: novel imaging of molecular targets is an emerging area crucial to the development of targeted drugs. Nat Clin Pract Oncol (2008) 1.08
Dynamics of targeted cancer therapy. Trends Mol Med (2012) 1.07
Ten things you should know about protein kinases: IUPHAR Review 14. Br J Pharmacol (2015) 1.06
MoKCa database--mutations of kinases in cancer. Nucleic Acids Res (2008) 1.06
Periostin-binding DNA aptamer inhibits breast cancer growth and metastasis. Mol Ther (2013) 1.06
A new approach for prediction of tumor sensitivity to targeted drugs based on functional data. BMC Bioinformatics (2013) 1.05
USP8 is a novel target for overcoming gefitinib resistance in lung cancer. Clin Cancer Res (2013) 1.04
β4 Integrin signaling induces expansion of prostate tumor progenitors. J Clin Invest (2013) 1.03
Statistical analysis of nonlinear dynamical systems using differential geometric sampling methods. Interface Focus (2011) 1.02
Safety and preliminary efficacy data of a novel casein kinase 2 (CK2) peptide inhibitor administered intralesionally at four dose levels in patients with cervical malignancies. BMC Cancer (2009) 1.02
Multi-tracer small animal PET imaging of the tumour response to the novel pan-Erb-B inhibitor CI-1033. Eur J Nucl Med Mol Imaging (2006) 1.01
Evaluating melanoma drug response and therapeutic escape with quantitative proteomics. Mol Cell Proteomics (2014) 1.00
Retention but significant reduction of BCR-ABL transcript in hematopoietic stem cells in chronic myelogenous leukemia after imatinib therapy. Int J Hematol (2008) 1.00
Oral antineoplastic agents: how do we care about adherence? Br J Clin Pharmacol (2015) 0.99
Peptide reporters of kinase activity in whole cell lysates. Biopolymers (2010) 0.98
Personalized medicine and pharmacogenetic biomarkers: progress in molecular oncology testing. Expert Rev Mol Diagn (2012) 0.97
Effects of a brief multimedia psychoeducational intervention on the attitudes and interest of patients with cancer regarding clinical trial participation: a multicenter randomized controlled trial. J Clin Oncol (2012) 0.97
Bortezomib induces apoptosis in esophageal squamous cell carcinoma cells through activation of the p38 mitogen-activated protein kinase pathway. Mol Cancer Ther (2008) 0.96
Spatial heterogeneity in drug concentrations can facilitate the emergence of resistance to cancer therapy. PLoS Comput Biol (2015) 0.96
A growing family: adding mutated Erbb4 as a novel cancer target. Cell Cycle (2010) 0.95
Ubiquitination-dependent regulation of signaling receptors in cancer. Genes Cancer (2010) 0.94
Timing and heterogeneity of mutations associated with drug resistance in metastatic cancers. Proc Natl Acad Sci U S A (2014) 0.94
The Impact of Microenvironmental Heterogeneity on the Evolution of Drug Resistance in Cancer Cells. Cancer Inform (2015) 0.94
How should we define STAT3 as an oncogene and as a potential target for therapy? JAKSTAT (2013) 0.93
Role of proprotein convertases in prostate cancer progression. Neoplasia (2012) 0.92
Compartmentalized cancer drug discovery targeting mitochondrial Hsp90 chaperones. Oncogene (2009) 0.92
A novel inhibitor of DNA polymerase beta enhances the ability of temozolomide to impair the growth of colon cancer cells. Mol Cancer Res (2009) 0.91
Tetrandrine induces autophagy and differentiation by activating ROS and Notch1 signaling in leukemia cells. Oncotarget (2015) 0.91
Prostate cancer regulatory networks. J Cell Biochem (2009) 0.91
Immunology in the clinic review series; focus on cancer: multiple roles for the immune system in oncogene addiction. Clin Exp Immunol (2012) 0.90
Steered molecular dynamics simulations reveal the likelier dissociation pathway of imatinib from its targeting kinases c-Kit and Abl. PLoS One (2009) 0.90
Grafting aptamers onto gold nanostars increases in vitro efficacy in a wide range of cancer cell types. Mol Pharm (2014) 0.90
A single-arm pilot phase II study of gefitinib and irinotecan in children with newly diagnosed high-risk neuroblastoma. Invest New Drugs (2011) 0.89
Comparison of Kinetic Models for Dual-Tracer Receptor Concentration Imaging in Tumors. Austin J Biomed Eng (2014) 0.88
Fluorescence resonance energy transfer biosensors for cancer detection and evaluation of drug efficacy. Clin Cancer Res (2010) 0.88
Kinase inhibitors can produce off-target effects and activate linked pathways by retroactivity. BMC Syst Biol (2011) 0.88
Preliminary data suggestive of a novel translational approach to mesothelioma treatment: imatinib mesylate with gemcitabine or pemetrexed. Thorax (2007) 0.88
Statistical properties and robustness of biological controller-target networks. PLoS One (2012) 0.88
Stathmin protein level, a potential predictive marker for taxane treatment response in endometrial cancer. PLoS One (2014) 0.87
Attacking a nexus of the oncogenic circuitry by reversing aberrant eIF4F-mediated translation. Mol Cancer Ther (2012) 0.87
Deregulation of cell signaling in cancer. FEBS Lett (2014) 0.87
Survivin: A molecular biomarker in cancer. Indian J Med Res (2015) 0.86
Tumor dormancy, oncogene addiction, cellular senescence, and self-renewal programs. Adv Exp Med Biol (2013) 0.86
DNA polymerase β as a novel target for chemotherapeutic intervention of colorectal cancer. PLoS One (2011) 0.86
Combination therapy: histone deacetylase inhibitors and platinum-based chemotherapeutics for cancer. Cancer Lett (2012) 0.86
The current state of targeted therapy in melanoma: this time it's personal. Semin Oncol (2012) 0.86
Omics Profiling in Precision Oncology. Mol Cell Proteomics (2016) 0.85
Dasatinib reverses the multidrug resistance of breast cancer MCF-7 cells to doxorubicin by downregulating P-gp expression via inhibiting the activation of ERK signaling pathway. Cancer Biol Ther (2015) 0.85
Amino acid Asp181 of 5'-flap endonuclease 1 is a useful target for chemotherapeutic development. Biochemistry (2009) 0.85
Gene expression changes as markers of early lapatinib response in a panel of breast cancer cell lines. Mol Cancer (2012) 0.85
Analysis of protein-protein interactions in cross-talk pathways reveals CRKL protein as a novel prognostic marker in hepatocellular carcinoma. Mol Cell Proteomics (2013) 0.84
CuAAC click chemistry accelerates the discovery of novel chemical scaffolds as promising protein tyrosine phosphatases inhibitors. Curr Med Chem (2012) 0.84
Identification of pathway deregulation--gene expression based analysis of consistent signal transduction. PLoS One (2012) 0.84